NeoGenomics Lifts Full-Year Outlook as Q2 Revenue Climbs 11% to $202M
NEO has more than doubled off its 52-week low of $4.72.
Summary
NeoGenomics posted Q2 2026 revenue of $202M (+11% YoY), GAAP net income of $2M, and raised its full-year revenue and adjusted EBITDA guidance.
Key Events · Earnings and Guidance · NEO
-
Revenue Beats, Up 11%
Q2 2026 revenue reached $202M, fueled by a 14% increase in clinical services and a 26% jump in NGS revenue.
-
Profitability Swings Positive
GAAP net income came in at $2M, reversing a $45M loss in Q2 2025; adjusted EBITDA rose 36% to $14M.
-
Full-Year Guidance Raised
Revenue guidance was lifted to $802M-$806M (from $797M-$803M), and adjusted EBITDA guidance was raised to $56M-$58M (from $55M-$57M).
-
Cash Generation Strengthens
Cash from operations totaled $20M, leaving the quarter with $146M in cash and equivalents.
Analysis · NEO · Industrial Applications And Services
A strong second quarter saw revenue climb 11% to $202 million, while adjusted EBITDA surged 36% to $14 million. The bottom line swung to a GAAP net income of $2 million from a $45 million loss a year ago, aided by an $11 million gain on debt extinguishment. Management raised full-year revenue and adjusted EBITDA guidance, underscoring confidence in the ongoing momentum. The results bolster the turnaround story following last year's impairment-driven losses and the recent convertible notes refinancing.
At the time of this filing, NEO was trading at $14.25 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $4.72 to $15.57. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.